This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Pharmacyclics® Appoints Joshua T. Brumm Executive Vice President Of Finance

SUNNYVALE, Calif., Aug. 14, 2012 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced the appointment of Joshua T. Brumm as its Executive Vice President of Finance. Mr. Brumm will have global responsibility for corporate finance, accounting, investor relations and IT.

Bob Duggan, CEO of Pharmacyclics stated, "We are very pleased to have Josh join our company. He brings with him a passion and energy that will continue to strengthen our management team as we prepare to become a commercial company.  He has significant expertise in corporate finance, corporate governance, and compliance and we look forward to the leadership he brings to the finance and executive management team."

Mr. Brumm was most recently Chief Financial Officer and Senior Vice President for ZELTIQ Aesthetics, Inc. having global responsibility for Finance, IT and Administration. Mr. Brumm also served ZELTIQ as Vice President, Corporate Development and Investor Relations, helping take the company public in October of 2011, as well as Senior Managing Director of International Sales launching the company's first commercial product in all markets outside of the United States and Canada. Prior to joining ZELTIQ, Mr. Brumm served as Director of Finance at Proteolix, Inc. (acquired by Onyx Pharmaceuticals), a private biotechnology company focused on the development of therapeutics targeting certain cancers, including Multiple Myeloma, and immunological conditions. Prior to joining Proteolix, Mr. Brumm held the position of Investment Banking Associate as a member of the West Coast Healthcare Team at Citigroup Global Markets, Inc. As an entrepreneur, Mr. Brumm founded Nu-Ag Distributing, LLC, an agricultural sales and consulting company specializing in cotton and grain production. He also served Nu-Ag Distributing as the company's Chief Executive Officer until its sale in June of 2007. Mr. Brumm started his career at Morgan Stanley as an Investment Banking Analyst for the West Coast Healthcare Team.  Mr. Brumm holds a B.A. in Business Administration, summa cum laude, from the University of Notre Dame.       

About Pharmacyclics

Pharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our corporate mission statement reads as follows: To build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious medical healthcare needs. To identify promising product candidates based on exceptional scientific development expertise, develop our products in a rapid, cost-efficient manner and to pursue commercialization and/or development partners when and where appropriate. We exist to make a difference for the better and these are important times to do that.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs